[1] Keitel V, Kreissl M C, Goetze T, et al. CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement[J]. J Hepatol,2026,84(4):829-836. [2] Zheng Z, Liu Y, Wang G, et al. In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis[J]. Cell Stem Cell,2026,33(4):589-604.e5. [3] Yashaswini C N, Cogliati B, Qin T, et al. Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis[J]. Sci Transl Med,2026,18(833):eadx0368. [4] Jaeckel E, Friedman S L, Hudecek M, et al. Chimeric antigen receptor (CAR) T-cell therapy: engineering immune cells to treat liver diseases[J]. J Hepatol,2025,83(5):1156-1171. [5] Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors[J]. N Engl J Med,2020,382(6):545-553. [6] Tur C, Eckstein M, Bucci L, et al. Effects of different B-cell-depleting strategies on the lymphatic tissue[J]. Ann Rheum Dis,2025,84(12):2065-2074. [7] Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus[J]. Nat Med,2022,28(10):2124-2132. [8] Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease-a case series with follow-up[J]. N Engl J Med,2024,390(8):687-700. [9] Schett G, Müller F, Taubmann J, et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases[J]. Nat Rev Rheumatol,2024,20(9):531-544. [10] Czaja A J. Review article: targeting the B cell activation system in autoimmune hepatitis[J]. Aliment Pharmacol Ther,2021,54(7):902-922. [11] Riveiro-Barciela M, Barreira-Díaz A, Esteban P, et al. Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: results from the ColHai registry[J]. Liver Int,2024,44(9):2303-2314. [12] Cai S, Chen Y, Ye C, et al. Anti-BCMA CAR-T for the treatment of IgG4-related disease: clinical assessment and single-cell transcriptomic analysis[J]. Lancet Rheumatol,2025,7(12):e834-e836. [13] Ellebrecht C T, Bhoj V G, Nace A, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease[J]. Science,2016,353(6295):179-184. [14] Müller F, Atreya R, Völkl S, et al. CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis[J]. N Engl J Med,2025,393(12):1239-1241. [15] Arjomandnejad M, Kopec A L, Keeler A M. CAR-T regulatory (CAR-Treg) cells: engineering and applications[J]. Biomedicines,2022,10(2):287. [16] Noyan F, Zimmermann K, Hardtke-Wolenski M, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor[J]. Am J Transplant,2017,17(4):917-930. [17] Oo Y H, Ackrill S, Cole R, et al. Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis[J]. JHEP Rep,2019,1(4):286-296. [18] Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies[J]. Nature,2020,583(7814):127-132. [19] Amor C, Fernández-Maestre I, Chowdhury S, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction[J]. Nat Aging,2024,4(3):336-349. [20] Dai H, Zhu C, Huai Q, et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models[J]. J Hepatol,2024,80(6):913-927. [21] Hayden P J, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)[J]. Ann Oncol,2022,33(3):259-275. [22] Ghilardi G, Fraietta J A, Gerson J N, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy[J]. Nat Med,2024,30(4):984-989. |